- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 12, 2022
Highlights
- Market Cap
- $591.81M
- Enterprise Value
- $492.59M
- EPS (TTM)
- -$0.00
- Total Revenue (TTM)
- $889.00K
- Gross Profit (TTM)
- -$2.18M
- EBITDA (TTM)
- -$112.46M
- Year Range
- $1.53 - $4.95
- Target Price
- $4.67
- ROA (TTM)
- -25.56%
- ROE (TTM)
- -28.44%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PROK Performance Chart
ProKidney Corp. (PROK) is down 21.4% since the beginning of the year. At $2 per share, PROK is trading 64.4% below its 52-week high of $5.
Loading charts...
Returns By Period
ProKidney Corp. (PROK) has returned -21.43% so far this year and -61.23% over the past 12 months.
ProKidney Corp.
- 1D
- -2.22%
- 1M
- 6.02%
- 6M
- -24.79%
- YTD
- -21.43%
- 1Y
- -61.23%
- 3Y*
- -45.53%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.42%
- 1M
- 1.94%
- 6M
- 8.74%
- YTD
- 10.66%
- 1Y
- 21.02%
- 3Y*
- 19.50%
- 5Y*
- 11.63%
- 10Y*
- 13.41%
PROK Monthly Returns History
Based on dividend-adjusted daily data since Jul 12, 2022, PROK's average daily return is +0.41%, while the average monthly return is +4.04%. At this rate, an investment would double in approximately 1.5 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jul 2025 with a return of +367.8%, while the worst month was Oct 2023 at -64.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, PROK closed higher 47% of trading days. The best single day was Jul 8, 2025 with a return of +515.0%, while the worst single day was Oct 12, 2023 at -31.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.61% | 13.13% | -20.09% | 6.15% | -3.68% | 11.48% | -13.73% | -21.43% | |||||
| 2025 | -2.37% | -25.45% | -28.76% | 1.07% | -18.38% | -18.08% | 367.83% | -14.80% | 2.54% | 26.45% | -27.45% | 0.90% | 32.54% |
| 2024 | -26.40% | 24.43% | 0.61% | 25.91% | 68.52% | -29.31% | -4.88% | 2.56% | -20.00% | -16.67% | 25.00% | -15.50% | -5.06% |
| 2023 | 52.04% | 12.08% | -3.17% | -16.61% | 28.60% | -7.83% | 14.57% | -33.07% | -46.62% | -64.41% | 3.07% | 5.95% | -74.05% |
| 2022 | 4.68% | -2.44% | -6.15% | 12.32% | -9.98% | -24.70% | -27.02% |
Benchmark Metrics
ProKidney Corp. has an annualized alpha of 102.00%, beta of 1.82, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 12, 2022.
- This stock participated in 274.63% of S&P 500 Index downside but only 115.17% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 102.00%
- Beta
- 1.82
- R²
- 0.01
- Upside Capture
- 115.17%
- Downside Capture
- 274.63%
Return for Risk
Risk / Return Rank
PROK ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ProKidney Corp. (PROK) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PROK | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.39 | ||
| Sortino ratioReturn per unit of downside risk | -3.38 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.30 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -1.00 | 2.28 | -3.28 |
| Martin ratioReturn relative to average drawdown | -1.31 | 9.88 | -11.20 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ProKidney Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProKidney Corp. was 96.29%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current ProKidney Corp. drawdown is 87.23%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -96.29%Apr 2025 | 2y 26d | — | 3y 4moMar 2023 - now |
Bear market2022 | -51.93%Dec 2022 | 1mo 14d | 1mo 11d | 2mo 25dNov 2022 - Feb 2023 |
Bear market2022 | -41.33%Aug 2022 | 23d | 2mo 24d | 3mo 17dJul 2022 - Nov 2022 |
Bear market2022 | -25.32%Jul 2022 | 3d | 10d | 13dJul 2022 - Jul 2022 |
2023 pullback2023 | -9.24%Feb 2023 | 7d | 20d | 27dFeb 2023 - Mar 2023 |
Drawdown Indicators
| PROK | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.29% | -56.78% | -39.51% |
Max Drawdown (1Y)Largest decline over 1 year | -65.86% | -9.10% | -56.76% |
Max Drawdown (3Y)Largest decline over 3 years | -96.09% | -18.90% | -77.19% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.23% | -0.45% | -86.78% |
Average DrawdownAverage peak-to-trough decline | -65.62% | -10.71% | -54.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 56.13% | 2.09% | +54.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ProKidney Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ProKidney Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PROK relative to other companies in the Biotechnology industry. Currently, PROK has a P/S ratio of 93,837.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PROK in comparison with other companies in the Biotechnology industry. Currently, PROK has a P/B value of 949.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PROK
Add ProKidney Corp. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PROK